source
- BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS workBridgeBio Oncology Therapeutics is replacing CEO Eli Wallace, putting its CSO Pedro Beltran in the role, and making board member Neil Kumar executive chairman. The changes come as there’s been grow…Endpoints · 3mo ago↗ source
- Pharma-backed petition calls on FDA to reform release of drug rejection lettersThe FDA for the first time is facing pharma-backed criticism of its new practice of publicly releasing partially redacted drug rejection letters. The law firm Covington & Burling, on behalf of an u…Endpoints · 3mo ago↗ source
- Revolution drug shows promise in early pancreatic cancerThe findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.